Zusammenfassung

Die Arzneitherapie ist das wichtigste Verfahren zur Behandlung von Epilepsien. Maßgebend für die Auswahl von Antiepileptika sind arzneimittelspezifische Variable (Anfallstyp, Nebenwirkungsprofil, Teratogenität, Pharmakokinetik, Interaktionspotenzial, Arzneiformen) und Patienten-abhängige Faktoren (Alter, Geschlecht, Komedikation, Begleitkrankheiten, genetischer Hintergrund) (Moshé et al. 2015, Gschwind und Seeck 2016). Mit geeigneten Arzneimitteln erreichen etwa 70% der Patienten eine Anfallsfreiheit. Unabhängig von prognostischen Faktoren werden die meisten Patienten mit dem zuerst eingesetzten Antiepileptikum anfallsfrei.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Backonja M, Beydoun A, Edwards KR, Schwartz SL, Fonseca V, Hes M, et al. for the Gabapentin Diabetic Neuropathy Study Group (1998): Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus. JAMA 280: 1831–1836Google Scholar
  2. Ben-Menachem E, Biton V, Jatuzis D, Abou-Khalil B, Doty P, Rudd GD (2007): Efficacy and safety of oral lacosamide as adjunctive therapy in adults with partial-onset seizures. Epilepsia 48: 1308–1317Google Scholar
  3. Beydoun A (1999): Monotherapy trials with gabapentin for partial epilepsy. Epilepsia 40 (Suppl 6): S13–S16Google Scholar
  4. Brodie MJ (2004): Pregabalin as adjunctive therapy for partial seizures. Epilepsia 45 Suppl 6: 19–27Google Scholar
  5. Brodie MJ, Perucca E, Ryvlin P, Ben-Menachem E, Meencke HJ (2007): Comparison of levetiracetam and controlledrelease carbamazepine in newly diagnosed epilepsy. Neurology 68: 402–408Google Scholar
  6. Carmichael K, Pulman J, Lakhan SE, Parikh P, Marson AG (2013): Zonisamide add-on for drug-resistant partial epilepsy. Cochrane Database Syst Rev. 2013 Dec 19; 12: CD001416Google Scholar
  7. Costa J, Fareleira F, Ascenção R, Borges M, Sampaio C, Vaz-Carneiro A (2011): Clinical comparability of the new antiepileptic drugs in refractory partial epilepsy: a systematic review and meta-analysis. Epilepsia 52: 1280–1291Google Scholar
  8. Deutsche Gesellschaft für Neurologie (2012): Leitlinien für Diagnostik und Therapie in der Neurologie. Erster epileptischer Anfall und Epilepsien im Erwachsenenalter. Internet: http://www.awmf.org/leitlinien/detail/ll/030-041.html
  9. Devinsky O (2011): Sudden, unexpected death in epilepsy. N Engl J Med 365: 1801–1811Google Scholar
  10. Dooley M, Plosker GL (2000): Levetiracetam. A review of its adjunctive use in the management of partial onset seizures. Drugs 60: 871–893Google Scholar
  11. Finnerup NB, Attal N, Haroutounian S, McNicol E, Baron R, Dworkin RH, Gilron I, Haanpää M, Hansson P, Jensen TS, Kamerman PR, Lund K, Moore A, Raja SN, Rice AS, Rowbotham M, Sena E, Siddall P, Smith BH, Wallace M (2015): Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol 14: 162–173Google Scholar
  12. French JA, Kanner AM, Bautista J, Abou-Khalil B, Browne T, Harden CL, Theodore WH, Bazil C, Stern J, Schachter SC, Bergen D, Hirtz D, Montouris GD, Nespeca M, Gidal B, Marks WJ Jr, Turk WR, Fischer JH, Bourgeois B, Wilner A, Faught RE Jr, Sachdeo RC, Beydoun A, Glauser TA; American Academy of Neurology Therapeutics and Technology Assessment Subcommittee; American Academy of Neurology Quality Standards Subcommittee; American Epilepsy Society Quality Standards Subcommittee; American Epilepsy Society Therapeutics and Technology Assessment Subcommittee (2004): Efficacy and tolerability of the new antiepileptic drugs, I: Treatment of new-onset epilepsy: report of the TTA and QSS Subcommittees of the American Academy of Neurology and the American Epilepsy Society. Epilepsia 45: 401–409Google Scholar
  13. Gamble CL, Williamson PR, Marson AG (2006): Lamotrigine versus carbamazepine monotherapy for epilepsy. Cochrane Database Syst Rev 25(1):CD001031Google Scholar
  14. Gschwind M, Seeck M (2016): Modern management of seizures and epilepsy. Swiss Med Wkly 2016 Jun 20; 146: w14310Google Scholar
  15. Goa KL, Ross SR, Chrisp P (1993): Lamotrigine. A review of its pharmacological properties and clinical efficacy in epilepsy. Drugs 46: 152–176Google Scholar
  16. Hitiris N, Brodie MJ (2006): Modern antiepileptic drugs: guidelines and beyond. Curr Opin Neurol 19: 175–180Google Scholar
  17. Koch MW, Polman SK (2009): Oxcarbazepine versus carbamazepine monotherapy for partial onset seizures. Cochrane Database Syst Rev. 2009 Oct 7;(4):CD006453Google Scholar
  18. LaRoche SM, Helmers SL (2004): The new antiepileptic drugs: scientific review. JAMA 291: 605–614Google Scholar
  19. Lynch BA, Lambeng N, Nocka K, Kensel-Hammes P, Bajjalieh SM, Matagne A, Fuks B (2004): The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. PNAS 101: 9861–9866Google Scholar
  20. Marson AG, Al-Kharusi AM, Alwaidh M, Appleton R, Baker GA, Chadwick DW, Cramp C, Cockerell OC, Cooper PN, Doughty J, Eaton B, Gamble C, Goulding PJ, Howell SJL, Hughes A, Jackson M, Jacoby A, Kellett M, Lawson GR, Leach JP, Nicolaides P, Roberts R, Shackley P, Shen J, Smith DS, Smith PEM, Tudor Smith C, Vanoli A, Williamson PR, on behalf of the SANAD Study group (2007a): The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. Lancet 369: 1000–1015Google Scholar
  21. Marson AG, Al-Kharusi AM, Alwaidh M, Appleton R, Baker GA, Chadwick DW, Cramp C, Cockerell OC, Cooper PN, Doughty J, Eaton B, Gamble C, Goulding PJ, Howell SJL, Hughes A, Jackson M, Jacoby A, Kellett M, Lawson GR, Leach JP, Nicolaides P, Roberts R, Shackley P, Shen J, Smith DS, Smith PEM, Tudor Smith C, Vanoli A, Williamson PR, on behalf of the SANAD Study group (2007b): The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalized and unclassifiable epilepsy: an unblinded randomized controlled trial. Lancet 369: 1016–1026Google Scholar
  22. Mbizvo GK, Dixon P, Hutton JL, Marson AG (2012): Levetiracetam add-on for drug-resistant focal epilepsy: an updated Cochrane Review. Cochrane Database Syst Rev. 2012 Sep 12; 9: CD001901Google Scholar
  23. McCorry D, Chadwick D, Marson A (2004): Current drug treatment of epilepsy in adults. Lancet Neurol 3: 729–735Google Scholar
  24. Milburn-McNulty P, Powell G, Sills GJ, Marson AG (2014): Sulthiame monotherapy for epilepsy. Cochrane Database Syst Rev. 2014 Mar 9; 3: CD010062Google Scholar
  25. Moore RA, Straube S, Wiffen PJ, Derry S, McQuay HJ (2009): Pregabalin for acute and chronic pain in adults. Cochrane Database Syst Rev. 2009 Jul 8; (3): CD007076Google Scholar
  26. Morello CM, Leckband SG, Stoner CP, Moorhouse DF, Sahagian GA (1999): Randomized double-blind study comparing the efficacy of gabapentin with amitriptyline on diabetic peripheral neuropathy pain. Arch Intern Med 159: 1931–1937Google Scholar
  27. Moshé SL, Perucca E, Ryvlin P, Tomson T (2015): Epilepsy: new advances. Lancet 385: 884–898Google Scholar
  28. National Institute for Health and Care Excellence (NICE) (2016): Epilepsies: the diagnosis and management. Clinical guideline CG137. Published: 11 January 2012, last updated February 2016. Internet: https://www.nice.org.uk/guidance/published?type=cg&title=epilepsies
  29. Nunes VD, Sawyer L, Neilson J, Sarri G, Cross JH (2013): Profile of lacosamide and its role in the long-term treatment of epilepsy: a perspective from the updated NICE guideline. Neuropsychiatr Dis Treat 9: 467–476Google Scholar
  30. Perucca E, Yasothan U, Clincke G, Kirkpatrick P (2008): Lacosamide. Nat Rev Drug Discov 7: 973–974Google Scholar
  31. Pulman J, Jette N, Dykeman J, Hemming K, Hutton JL, Marson AG (2014): Topiramate add-on for drug-resistant partial epilepsy. Cochrane Database Syst Rev. 2014 Feb 25; 2: CD001417Google Scholar
  32. Shorvon SD (2009): Drug treatment of epilepsy in the century of the ILAE: the second 50 years, 1959–2009. Epilepsia 50 Suppl 3: 93–130Google Scholar
  33. Steinhoff BJ (2014): Efficacy of perampanel: a review of pooled data. Epilepsia 55 Suppl 1: 9–12Google Scholar
  34. Tomson T, Battino D, Perucca E (2016): Valproic acid after five decades of use in epilepsy: time to reconsider the indications of a time-honoured drug. Lancet Neurol 15: 210–218Google Scholar
  35. Veroniki AA, Cogo E, Rios P, Straus SE, Finkelstein Y, Kealey R, Reynen E, Soobiah C, Thavorn K, Hutton B, Hemmelgarn BR, Yazdi F, D’Souza J, MacDonald H, Tricco AC (2017): Comparative safety of anti-epileptic drugs during pregnancy: a systematic review and network meta-analysis of congenital malformations and prenatal outcomes. BMC Med. 2017 May 5;15(1): 95Google Scholar

Copyright information

© Springer-Verlag GmbH Germany 2017

Authors and Affiliations

  1. 1.Pharmakologisches Institut der Universität HeidelbergHeidelbergDeutschland

Personalised recommendations